Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Alvotech ( (ALVO) ) has provided an update.
On June 25, 2025, Alvotech announced positive topline results from a confirmatory efficacy study for AVT23, a proposed biosimilar to Xolair® (omalizumab). The study, conducted in collaboration with Kashiv Biosciences and Advanz Pharma, demonstrated equivalence in therapeutic endpoints and comparable safety between AVT23 and the reference biologic in patients with Chronic Spontaneous Urticaria. This development marks a significant step in Alvotech’s efforts to increase global patient access to biosimilar medicines, with regulatory applications underway in the UK and Europe.
The most recent analyst rating on (ALVO) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s score is primarily influenced by its financial performance, which indicates rapid growth but significant financial instability. The earnings call provided a positive outlook with raised guidance and strategic product launches. However, technical analysis shows bearish signals and valuation is moderately high, affecting the overall score.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotech company focused on the development and manufacturing of biosimilar medicines. The company aims to be a leader in the biosimilar industry by providing high-quality, cost-effective products through a fully integrated approach. Alvotech has a pipeline of biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. The company has formed strategic commercial partnerships to expand its reach in various global markets.
Average Trading Volume: 204,780
Technical Sentiment Signal: Sell
Current Market Cap: $2.76B
See more data about ALVO stock on TipRanks’ Stock Analysis page.